While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...
Compass Therapeutics will still submit tovecimig for approval despite the OS miss.
Compass Pathways may be the first to benefit from an accelerated approval process.
The Consumer Policy Center estimated that Compass’ market share was up to 40 percent after its deal for Anywhere Real Estate.